This bill establishes a coordinating committee within the federal government to streamline how multiple agencies oversee biotechnology products. The committee, chaired by the Office of Science and Technology Policy director, will include representatives from the Department of Agriculture, Health and Human Services, Environmental Protection Agency, and other relevant agencies. It affects biotechnology companies, researchers, and any organization developing products from genetically modified plants, animals, or microorganisms, while excluding human medical research and FDA-regulated drugs. The committee must submit reports to Congress within one year and annually thereafter detailing its efforts to align regulatory timelines, reduce duplicative reviews, identify points of contact for different product types, and develop a unified process for determining whether biotech products could occur naturally. The Government Accountability Office will review the committee's effectiveness within two years and provide Congress with recommendations for eliminating regulatory gaps and overlaps.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.